PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Organ Dysfunction Varies Widely in Preterm Late-Onset Bacteremia

neonatal sepsislate-onset bacteremiapreterm infantsnSOFAorgan dysfunctioncoagulase-negative staphylococciantibiotic stewardshipcohort studyNICUsepsis definitions Clinical Pharmacy Practice

Background Information

Preterm infants show diverse organ dysfunction patterns during late-onset bacteremia.

Understanding organ dysfunction variability in preterm infants with late-onset bacteremia can enhance neonatal sepsis management beyond binary classifications. In 221 preterm infants, organ dysfunction showed substantial variability, with a median maximum Neonatal Sequential Organ Failure Assessment (nSOFA) score of 6 (IQR, 1-9) for Gram-negative and 3 (IQR, 0-9) for Gram-positive bacteremia. This study highlights the limitations of relying solely on binary microbiologic criteria, suggesting a need for more nuanced frameworks to assess neonatal sepsis outcomes effectively. Neonatal sepsis management benefits from understanding the heterogeneity in organ dysfunction beyond binary pathogen classifications.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Liu S, Missigman E, Al Gharaibeh FN, Park WY, Lawler B, Kuiper JR, Makker K, Moreira AG, Wynn JL, Aziz KB

Citation: Liu S, Missigman E, Al Gharaibeh FN, et al. Heterogeneity of Critical Organ Dysfunction During Late-Onset Bacteremia in Preterm Infants. JAMA network open. 2026;9(9):e2632792. doi:10.1001/jamanetworkopen.2026.32792

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →